IN THE NEWS

Year: 2025

18June2025

Ritedose Unveils State-of-the-Art Distribution and Logistics Facility at Ritedose Performance Park

COLUMBIA, SC, June 18, 2025 – The Ritedose Corporation, a leading pharmaceutical manufacturer specializing in Blow-Fill-Seal (BFS) technology, today unveiled its new distribution and logistics facility at Performance Park during a ribbon-cutting ceremony. The grand opening event included Ritedose CEO…

Stakeholders open the Ritedose distribution and logistics facility at Performance Park. L–R: Brian Taylor, VP Business Development, Miller Valentine Construction Jeff Ruble, Director, Richland County Economic Development Ashely Teasdel, Deputy Secretary, SC Dept. of Commerce Jody Chastain, CEO, Ritedose Jesica Mackey, Richland County Council District 9 Daniel Rickenmann, Mayor, City of Columbia Ronald Rhames, Fmr. President, Midlands Technical College Greg Little, President, Midlands Technical College

19May2025

Ritedose Pharmaceuticals Receives FDA Approval for Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL)*—Addressing Nationwide Shortage of the Essential Drug

COLUMBIA, SC May 20, 2025 —Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), the largest sterile contract development manufacturing organization (CDMO) in the US specializing in aseptic unit-dose medication production using Blow-Fill-Seal (BFS) technology, received US Food and Drug…

Ritedose Pharmaceuticals Receives FDA Approval for Albuterol Sulfate Inhalation Solution

1May2025

Ritedose Pharmaceuticals Receives FDA Approval for Generic Formoterol Fumarate Inhalation Treatment for Respiratory Illness

COLUMBIA, SC May 1, 2025 — Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), was granted approval by the US Food and Drug Administration (FDA) to manufacture and market generic formoterol fumarate inhalation solution (20 mcg/2 mL), a treatment…

Blow Fill Seal machines in a manufacturing facility

15April2025

Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of new COPD Drug Ohtuvayre

COLUMBIA, S.C. April 16, 2025 – Anticipating a rising need for individually wrapped vial medication manufacturing, The Ritedose Corporation, Inc. (Ritedose) is adding a seventh Syntegon packaging line to its state-of-the-art manufacturing facility that will double the company’s capacity.

single-vial packaging line in manufacturing facility

5March2025

Ritedose Expands Commitment to Service with 1,000 Hours of Purpose Initiative

COLUMBIA, S.C. – March 6, 2025 – The Ritedose Corporation (Ritedose) announces a groundbreaking new volunteer program: 1,000 Hours of Purpose. “1,000 Hours of Purpose” is a year-long initiative that provides Ritedose employees with the opportunity to dedicate their time,…

20January2025

Ritedose and Newberry College Forge Strategic Partnership to Launch Pharmaceutical Manufacturing Program

COLUMBIA, S.C. Jan. 21, 2025 – In response to the growing demand for skilled professionals in South Carolina’s life sciences sector, The Ritedose Corporation has partnered with Newberry College to launch a new Pharmaceutical Manufacturing program, set to begin in…

smiling male student holding book with text overlay: preparing tomorrow's life science leaders

FEATURED NEWS

18th June 2025

Ritedose Unveils State-of-the-Art Distribution and Logistics Facility at Ritedose Performance Park

15th April 2025

Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of new COPD Drug Ohtuvayre

16th September 2024

Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*

Ohtuvayre box with two individually wrapped vials with text overlay: development and manufacturing partner

11th July 2024

Ritedose, the Leading Pharmaceutical Manufacturer (CDMO) Specializing in Sterile Blow-Fill-Seal, Expands its BFS Capacity to Meet the Growing Demand f…

interior of large warehouse with forklifts in foreground and text overlay: we are expanding

18th January 2022

RECEIVE THE LATEST NEWS

Get a healthy dose of all things Ritedose. Subscribe now for breaking news alerts, updates, previews, and more.

Year: 2025

Ritedose Unveils State-of-the-Art Distribution and Logistics Facility at Ritedose Performance Park

Ritedose Pharmaceuticals Receives FDA Approval for Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL)*—Addressing Nationwide Shortage of the Essential Drug

Ritedose Pharmaceuticals Receives FDA Approval for Generic Formoterol Fumarate Inhalation Treatment for Respiratory Illness

Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of new COPD Drug Ohtuvayre

Ritedose Expands Commitment to Service with 1,000 Hours of Purpose Initiative

Ritedose and Newberry College Forge Strategic Partnership to Launch Pharmaceutical Manufacturing Program

FEATURED NEWS

Ritedose Unveils State-of-the-Art Distribution and Logistics Facility at Ritedose Performance Park

Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of new COPD Drug Ohtuvayre

Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*

Ritedose, the Leading Pharmaceutical Manufacturer (CDMO) Specializing in Sterile Blow-Fill-Seal, Expands its BFS Capacity to Meet the Growing Demand f…

The Ritedose Corporation Announces Revolutionary Liquid Med Dispenser SuredoseRx™ to launch in first quarter

Novo Holdings to acquire Ritedose

Ritedose Efficiency Innovation Yields Up to 25% Increase in CDMO Production Capability

RECEIVE THE LATEST NEWS

TAGS CLOUD

Quick Links

Receive the latest news.

Year: 2025

FEATURED NEWS

RECEIVE THE LATEST NEWS

TAGS CLOUD

Tags

Quick Links

Receive the latest news.